US Department of Veterans Affairs’ leadership is hoping that insights into how the VA made critical Alzheimer’s drug coverage decisions can help clear up confusion and media narratives that have suggested the department is offering more access to the new anti-amyloid drugs than the Centers for Medicare and Medicaid Services.
The misconceptions of the VA’s coverage of Biogen, Inc. and Eisai Co., Ltd.’s Aduhelm (aducanumab-avwa) and Leqembi (lecanemab-irmb)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?